Overview

TTI has two main areas of focus: cytoprotection and immune regulation.

In the cytoprotection space, TTI is developing a recombinant growth factor that has proliferative, anti-apoptotic and anti-inflammatory activity and can reduce permeability. It is being developed for two indications, interstitial cystitis and necrotizing enterocolitis, that are characterized by dysfunction in the epithelium of the bladder and GI tract, respectively.

In the immune regulation field, TTI has a strong interest in pathways which downregulate the immune system. These negative pathways are frequently exploited by tumour cells to evade immune-mediated destruction. TTI is developing biologics which block these interactions and mobilize anti-cancer responses. Activating suppressive pathways also holds promise for treating autoimmune/inflammatory diseases and controlling unwanted responses in transplant patients.